Medicina
Departamento
GlaxoSmithKline (Spain)
Madrid, EspañaPublicaciones en colaboración con investigadoras/es de GlaxoSmithKline (Spain) (6)
2019
-
Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain
ClinicoEconomics and Outcomes Research, Vol. 11, pp. 757-765
2016
-
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic copd spanish patients
International Journal of COPD, Vol. 11, pp. 123-132
2010
-
Geographical variations in the prevalence of COPD in Spain: Relationship to smoking, death rates and other determining factors
Archivos de Bronconeumologia, Vol. 46, Núm. 10, pp. 522-530
-
Recent trends in COPD prevalence in Spain: A repeated cross-sectional survey 1997-2007
European Respiratory Journal, Vol. 36, Núm. 4, pp. 758-765
2006
-
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy, Vol. 57, Núm. 3, pp. 536-545
2003
-
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults
Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836